In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celldex Therapeutics, Inc.

https://www.celldex.com/

Latest From Celldex Therapeutics, Inc.

Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks

The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.

Commercial Clinical Trials

Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.

Cancer Companies

Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.

Companies Research & Development

Pfizer Signs Paxlovid Agreement As China Cases Soar

Pfizer has signed up with a state-owned enterprise for the distribution of its recently approved oral antiviral for COVID-19 in China, where daily case counts are surging amid some tightening restrictions.

China Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Avant Immunotherapeutics, Inc.
    • CuraGen Corporation
    • Kolltan Pharmaceuticals, Inc.
    • Xetrios Therapeutics Inc.
UsernamePublicRestriction

Register